Breast Cancer
Find comprehensive information on Breast Cancer, also known as Carcinoma of the Breast, Mammary Carcinoma, and other related terms. This resource offers guidance on healthcare, clinical documentation, and medical coding for Breast Carcinoma, supporting accurate diagnosis and billing. Learn about symptoms, staging, and treatment options for Breast Cancer, crucial for medical professionals and patients seeking information.
Malignant tumor originating in breast tissue, often in milk ducts or lobules.
Lump, nipple changes, skin dimpling, swelling, pain. May be asymptomatic.
Oncology clinics, breast centers, hospitals, primary care offices.
ICD-10 Code Families
Complete code families applicable to C50.919
When to use each related code
| Description | When to use |
|---|---|
| Malignant tumor of breast tissue. | Use for invasive or in situ breast cancers. Code morphology and laterality. |
| Non-cancerous breast lump. | Use for fibroadenomas, cysts, and other benign breast masses. Specify type. |
| Abnormal breast tissue changes. | Use for ductal or lobular hyperplasia, atypical hyperplasia. Indicates increased risk. |
Best-practice checklist
- ✓Breast cancer diagnosis: Document laterality (left, right, bilateral).
- ✓Breast cancer: Specify tumor size, grade, and stage (TNM).
- ✓Document ER, PR, and HER2 receptor status for breast cancer.
- ✓If metastatic, specify sites of breast cancer metastasis.
- ✓Breast cancer: Document surgical margins and lymph node involvement.
Common pitfalls to avoid
Missing or incorrect laterality (right, left, bilateral) for breast cancer impacts staging and treatment data accuracy.
Unspecified histology codes lack detail for accurate cancer reporting, impacting quality measures and research.
Miscoding in situ versus invasive breast cancer affects staging, treatment planning, and survival analysis.
Best-practice tips
- 01Annual mammograms, starting at age 40, for early detection.
- 02Clinical breast exams for timely diagnosis and risk assessment.
- 03Genetic testing BRCA1/2 for high-risk individuals.
- 04Breast self-awareness for prompt identification of changes.
- 05Healthy lifestyle choices for reduced breast cancer risk.
Step-by-step checklist
- 1
Verify patient age and risk factors (family history, genetics).
- 2
Confirm physical exam findings (palpable mass, skin changes).
- 3
Review imaging results (mammogram, ultrasound, MRI).
- 4
Check biopsy results if available (pathology report).
Ready-to-paste narrative
Patient presents with concerns regarding breast changes, prompting evaluation for breast cancer. Symptoms include palpable breast lump, noted as (size and location), accompanied by (mention specific symptoms e.g., nipple discharge, skin changes such as dimpling or peau d'orange, axillary lymphadenopathy). Patient history includes (mention relevant family history of breast cancer, genetic predispositions like BRCA mutations, hormonal factors, age, and menopausal status). Physical examination reveals (detailed findings of breast exam including characteristics of the lump, nipple assessment, and axillary examination). Diagnostic mammogram performed on (date) demonstrated (BIRADS classification and specific findings e.g., mass, calcifications, architectural distortion). Ultrasound of the breast was performed on (date) and showed (characteristics of the lesion, including size, shape, margins, and vascularity). Biopsy performed on (date) confirmed invasive ductal carcinoma (or specific histological subtype), with (mention receptor status ER, PR, HER2). Staging workup, including (mention specific tests like chest X-ray, CT scan, bone scan), is underway to assess for metastatic disease. The patient was counseled on treatment options, including surgery (lumpectomy, mastectomy), chemotherapy, radiation therapy, targeted therapy, and hormonal therapy. Treatment plan will be determined based on staging results, molecular subtype, patient preferences, and multidisciplinary team recommendations. Follow-up appointment scheduled for (date) to discuss treatment plan and address any further concerns. Diagnosis: Breast cancer (ICD-10 code C50.).
Common questions and answers
What are the latest evidence-based guidelines for neoadjuvant chemotherapy in locally advanced breast cancer HER2-positive patients?+
Neoadjuvant chemotherapy (NAC) is a standard treatment approach for locally advanced HER2-positive breast cancer. The current National Comprehensive Cancer Network (NCCN) guidelines recommend a combination of taxane-based and anthracycline-based chemotherapy along with anti-HER2 targeted therapy (trastuzumab and pertuzumab). The optimal duration and sequencing of NAC are still being investigated, but common regimens include docetaxel, carboplatin, and trastuzumab emtansine (T-DM1). Pathologic complete response (pCR) following NAC is a strong predictor of improved disease-free survival and overall survival in these patients. Consider implementing the latest NCCN guidelines in your practice to ensure optimal patient outcomes. Explore how our resources can help you stay up-to-date on the latest advancements in neoadjuvant chemotherapy regimens for HER2-positive breast cancer.
How can I differentiate between inflammatory breast cancer and a breast infection based on clinical presentation and diagnostic workup?+
Differentiating between inflammatory breast cancer (IBC) and a breast infection can be challenging due to overlapping symptoms such as erythema, edema, and pain. However, IBC typically presents with a rapid onset of symptoms, peau d'orange appearance of the breast skin, and may or may not have a palpable mass. Infections, on the other hand, often involve fever and localized tenderness. Diagnostic workup for IBC includes mammography, ultrasound, and biopsy to confirm the diagnosis. Biopsy is crucial for distinguishing IBC from infection. In cases of suspected IBC, prompt diagnosis and treatment are critical. Learn more about the key differentiating features and diagnostic approaches for IBC and breast infection to enhance your clinical decision-making. Explore how our resources can aid in the accurate and timely diagnosis of these conditions.
What are the best strategies for managing treatment-related adverse events, such as cardiotoxicity and neuropathy, in patients receiving chemotherapy for breast cancer?+
Chemotherapy for breast cancer can lead to various adverse events, including cardiotoxicity from anthracyclines and neuropathy from taxanes. Strategies for managing cardiotoxicity include close monitoring of left ventricular ejection fraction (LVEF), using dexrazoxane as a cardioprotectant when indicated, and managing hypertension and other cardiovascular risk factors. For neuropathy, dose modifications, switching to a different chemotherapy agent, or supportive care medications like gabapentin or pregabalin can be considered. Early identification and management of these adverse events are crucial for improving patient quality of life and treatment adherence. Explore how our comprehensive resources can help you effectively manage treatment-related adverse events in breast cancer patients and optimize their treatment journey. Consider implementing these strategies in your practice to minimize treatment-related complications.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.